Warfarin is the most commonly pre-scribed oral anticoagulant world-wide and is likely to remain an important drug into the future, based on its proven efficacy and the lack of cost-effective al-ternatives for indications such as chronic atrial fibrillation.1 Despite almost 60 years of clinical experience with its use, warfarin is still a major cause of adverse drug events and hospital admissions,2-5 and optimal management remains a challenge. Warfarin-related hemorrhagic events6,7 and thromboembolic events re-sulting from therapeutic failures8,9 result in significant morbidity and mortality in individuals and substantial costs to the health-care system.4 A number of factors complicate war-farin management in the period following discharge from the hospital. Adverse event rates are intrinsically higher after warfarin initiation, with bleeding and re-current thromboembolic events occurring more frequently.7,10,11 The requirement for closer international normalized ratio (INR) monitoring early in therapy or be-cause of destabilized postdischarge anti-coagulant control12 often represents a sig-nificant burden for patients with mobility or transportation problems.13 Some pa

Similar works

Full text

oai:CiteSeerX.psu: time updated on 11/2/2017

This paper was published in CiteSeerX.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.